Magnetic resonance imaging (MRI) is a foundation of medical imaging and plays a crucial role in the diagnosis and monitoring of various diseases. With advancements in technology and medicine, MRI has become the technique of choice in evaluating many diseases due to its high spatial and temporal resolution, soft tissue contrast, and lack of ionizing radiation. To further enhance the diagnostic accuracy of MRI, several techniques are being explored, including more precise scanning technology, computer-aided analysis of scans, optimized scanning protocols, and the use of injectable contrast agents.
Contrast agents are essential in contrast-enhanced MRI (CE-MRI) to improve resolution and enhance anatomical features. While gadolinium-based contrast agents (GBCAs) have been widely used, there is growing concern about the potential risks associated with unbound gadolinium ions.
While research for alternative contrast agents is ongoing, current Gd-based agents remain essential in MRI enhancement. Technological advancements in software, such as image processing and artificial intelligence (AI), hold immense potential but may require further development before integration into clinical practice. The future of MRI enhancement may involve Gd-based agents while exploring new approaches.
At the forefront of MRI innovation, Guerbet recognized the importance of patient safety, sustainability, and responsible usage of contrast agents is recognized. With safety concerns raised following reports of Nephrogenic System Fibrosis (NSF) and gadolinium retention, and evidence of gadolinium in surface, ground and drinking water, we believe that that lower is better for the use of gadolinium in contrast-enhance MRI, and it is time to “Aim low”. We achieve this by creating a dedicated international educational platform for radiographers and radiologists to provide evidence-based data on patient-specific contrast media dosing protocols for all diseases.
Guerbet is a leading force in the development, research, and manufacturing of contrast agents, and associated technologies. We are dedicated to taking a more responsible approach to the use of gadolinium, benefiting patients, the environment, and the radiology community.
Through our commitment to innovation, we strive to improve existing products and address unmet medical needs. We invest heavily in research and development to pioneer innovations in the field. Our collaborations with partners for next-generation scanners and exploration of supercomputing and AI in image analysis demonstrate our dedication to pushing the boundaries of MRI innovation.
For further information about our contributions to MRI innovation, please visit our website at https://www.innovation4mri.com/
